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Abstract 
High-fat (HF) diet-induced obesity is a major risk factor for the development of insulin resistance and 
hepatic steatosis. We examined the hypothesis that bardoxolone methyl (BM) would prevent the 
development of insulin resistance and hepatic steatosis in mice fed a HF diet. C57BL/6J male mice were 
fed a lab chow (LC), HF (40% fat), or HF diet supplemented with 10 mg/kg/day BM orally for 21 weeks. 
Glucose metabolism was assessed using a glucose tolerance test (GTT) and insulin sensitivity test (IST). 
Signalling molecules involved in insulin resistance, inflammation, and lipid metabolism were examined in 
liver tissue via western blotting and RT-PCR. BM prevented HF diet-induced insulin resistance and 
alterations in the protein levels of protein tyrosine phosphatase 1B (PTP1B), forkhead box protein O1 
(FOXO1) and BDNF, and expression of the insulin receptor (IR), IRS-1 and glucose-6-phosphatase 
(G6Pase) genes. Furthermore, BM prevented fat accumulation in the liver and decreases in the β-
oxidation gene, peroxisomal acyl-coenzyme A oxidase 1 (ACOX) in mice fed a HF diet. In the livers of HF 
fed mice, BM administration prevented HF diet-induced macrophage infiltration, inflammation as 
indicated by reduced IL-6 and signal transducer and activator of transcription 3 (STAT3) protein levels and 
TNFα mRNA expression, and increased nuclear factor-like 2 (Nrf2) mRNA expression and nuclear protein 
levels. These findings suggest that BM prevents HF diet induced insulin resistance and the development 
of hepatic steatosis in mice fed a chronic HF diet through modulation of molecules involved in insulin 
signalling, lipid metabolism and inflammation in the liver. 
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High-fat (HF) diet-induced obesity is a major risk factor for the development of insulin resistance and 
hepatic steatosis. We examined the hypothesis that bardoxolone methyl (BM) would prevent the 
development of insulin resistance and hepatic steatosis in mice fed a HF diet. C57BL/6J male mice 
were fed a lab chow (LC), HF (40% fat), or HF diet supplemented with 10 mg/kg/day BM orally for 21 
weeks. Glucose metabolism was assessed using a glucose tolerance test (GTT) and insulin sensitivity 
test (IST). Signalling molecules involved in insulin resistance, inflammation, and lipid metabolism were 
examined in liver tissue via western blotting and RT-PCR. BM prevented HF diet-induced insulin 
resistance and alterations in the protein levels of protein tyrosine phosphatase 1B (PTP1B), forkhead 
box protein O1 (FOXO1) and BDNF, and expression of the insulin receptor (IR), IRS-1 and glucose-6-
phosphatase (G6Pase) genes. Furthermore, BM prevented fat accumulation in the liver and decreases 
in the β-oxidation gene, peroxisomal acyl-coenzyme A oxidase 1 (ACOX) in mice fed a HF diet. In the 
livers of HF fed mice, BM administration prevented HF diet-induced macrophage infiltration, 
inflammation as indicated by reduced IL-6 and signal transducer and activator of transcription 3 
(STAT3) protein levels and TNFα mRNA expression, and increased nuclear factor-like 2 (Nrf2) mRNA 
expression and nuclear protein levels. These findings suggest that BM prevents HF diet induced insulin 
resistance and the development of hepatic steatosis in mice fed a chronic HF diet through modulation 
of molecules involved in insulin signalling, lipid metabolism and inflammation in the liver.  
  
1. Introduction 
Obesity is a major risk factor for the development of insulin resistance, type 2 diabetes and hepatic 
steatosis (Kahn, Hull and Utzschneider, 2006,Forouhi and Wareham, 2010). It is widely accepted that 
high-fat (HF) diet-induced obesity causes increased fat accumulation, macrophage infiltration and 
chronic inflammation in peripheral tissues (Xu, Barnes, Yang et al., 2003,Weisberg, McCann, Desai et 
al., 2003). Increased fat accumulation and inflammation promotes insulin resistance and tissue injury in 
peripheral tissues involved in glucose and fat metabolism, such as the liver (Xu et al., 2003,Weisberg et 
al., 2003). A number of studies provide direct evidence demonstrating a link between obesity-
associated inflammation and insulin resistance, and hepatic steatosis (Emanuela, Grazia, Marco de et 
al., 2012,Ginsberg, 2006,Qureshi and Abrams, 2007). However, there is a need to develop novel 
therapeutic approaches targeting hepatic inflammation and to improve obesity-induced insulin 
resistance and hepatic steatosis.  
The activation of inflammatory molecules can promote the expression of the negative regulators of 
insulin signalling, protein tyrosine phosphatase B (PTP1B) and SOCS3 (Zabolotny, Kim, Welsh et al., 
2008,Hong, Nguyen and Gao, 2001). PTP1B levels are increased in the liver of HF diet-induced obese 
mice, which contributes to the development of insulin resistance by reducing insulin signalling through 
inhibition of insulin receptor (IR) and insulin receptor substrate 1 (IRS-1) activation (Lam, Covey, Lewis 
et al., 2006,Goldstein, Bittner-Kowalczyk, White et al., 2000). SOCS3 is another important molecule 
which impairs insulin signal transduction in the liver through its inhibition of the binding of IR to IRS-1 
(Ueki, Kondo and Kahn, 2004). Furthermore, activation of hepatic insulin signalling results in the 
inactivation of forkhead box protein O1 (FOXO1), which is a transcription factor inhibiting genes such 
as glucose-6-phosphatase (G6Pase) for endogenous glucose production via gluconeogenesis (Nakae, 
Kitamura, Silver et al., 2001,German, Kim, Schwartz et al., 2009). When insulin signalling is impaired, 
through inhibition by PTP1B or SOCS3, and activation of FOXO1, this leads to the promotion of 
glucose production and a reduction in glucose reuptake, leading to glucose intolerance and insulin 
resistance in obesity (Nakae et al., 2001,German et al., 2009). Brain-derived neurotrophic factor 
(BDNF) also plays an import role in insulin action as it has been found to modulate hepatic glucose 
metabolism via its actions on glucokinse (GK) in obese insulin resistant rats (Kuroda, Yamasaki, 
Matsuhisa et al., 2003). In the liver, GK enhances glycolysis, resulting in reduced blood glucose levels 
(Hariharan, Farrelly, Hagan et al., 1997). 
A HF diet is known to cause fat accumulation in the liver, which can progressively worsen to hepatic 
steatosis (Marchesini, Brizi, Bianchi et al., 2001). Hepatic lipid homeostasis is regulated by a number of 
genes that promote lipogenesis, including ACC, FAS and SCD1, and β oxidation, such as ACOX 
(Musso, Gambino and Cassader, 2009). Hepatic fat accumulation leads to macrophage infiltration 
which promotes the production of proinflammatory cytokines, such as interleukin-6 (IL-6), tumour 
necrosis factor alpha (TNFα) and IL-1 β (McArdle, Finucane, Connaughton et al., 2013). Increased IL-6 
has been found to enhance inflammatory signalling by increasing signal transducer and activator of 
transcription 3 (STAT3) levels, which promotes cytokine dependent signalling by increasing the 
expression of inflammatory genes such as IL-6 (Yang, Liao, Agarwal et al., 2007). In addition, inhibitor 
of nuclear factor kappa-B kinase subunit beta (IKKβ), and inhibitor of nuclear factor kappa-B kinase 
subunit epsilon (IKKε) are important proinflammatory signalling molecules upstream of the transcription 
factor, nuclear factor kappa-B (NFκB), which promote PTP1B and SOCS3 activation (Zabolotny et al., 
2008,Hong et al., 2001,Napetschnig and Wu, 2013).  
The oleanolic acid synthetic derivative, bardoxolone methyl (BM) has attracted wide attention due to its 
anti-inflammatory effects (Liby and Sporn, 2012,Wang, Garvin, D'Ambrosio et al., 2011,Reisman, 
Chertow, Hebbar et al., 2012). Its ability to directly up-regulate the potent anti-inflammatory molecule, 
nuclear factor-like 2 (Nrf2), has demonstrated therapeutic benefits in human clinical trials for treating 
chronic kidney disease and advanced solid tumours (NIH, 2012,Pergola, Raskin, Toto et al., 2011,Liby, 
Yore and Sporn, 2007,Hong, Kurzrock, Supko et al., 2012). BM has also been found to directly 
influence the activity of proinflammatory signalling through IKKβ (Ahmad, Raina, Meyer et al., 2006). 
Furthermore, a recent study demonstrated that 2 week administration of BM decreased hepatic 
inflammation in diet-induced obese mice (Saha, Reddy, Konopleva et al., 2010). In addition, previous 
studies have demonstrated that oral administration of a derivative of BM, 1-[2-cyano-3,12-dioxooleana-
1,9(11)-dien-28-oyl]imidazole (CDDO-Im), prevents HF diet-induced obesity and attenuates diabetes in 
mice (Uruno, Furusawa, Yagishita et al., 2013,Shin, Wakabayashi, Yates et al., 2009). In this study, we 
investigated whether chronic oral BM administration in mice fed a HF diet for 21 weeks could prevent 
insulin resistance and liver injury in mice fed a HF diet. We also examined signalling molecules involved 
in insulin resistance, inflammation, and lipid metabolism in liver tissue.  
2. Materials and Methods 
2.1. Animals and HF diet-induced obesity model 
Male C57BL/6J mice (12 weeks old) were purchased from the Animal Resource Centre (Perth, Western 
Australia) and maintained in the animal facility at the University of Wollongong. The experiments were 
performed in accordance with the Australian Code of Practice for the Care and Use of Animals for 
Scientific Purposes. All procedures were approved by the Animal Ethics Committee, University of 
Wollongong, Wollongong, Australia (AE 12/15). Mice were housed in environmentally controlled 
conditions (temperature 22 °C, 12hr light/dark cycle) and 1 week after acclimatisation were randomly 
divided into 3 groups (n=7 per group). For the next 21 weeks one group of mice were fed a lab chow 
(LC) diet (5% of energy as fat; Vella Stock Feeds, Doonside, New South Wales, Australia), and the 
other two groups a HF diet (40% of energy as fat; SF11-095, Specialty Feeds, Glen Forrest, Western 
Australia), and mice in the treatment group were fed a HF diet for 21 weeks and an oral daily dose of 
BM (10 mg/kg) in their drinking water (Table 1). (Final average body weight after 21 weeks: LC, 27.15g; 




Table 1 Composition of the high-fat and lab chow diets 
 High-fat diet Lab chow diet 











High-fat diet: Casein (Acid), Sucrose, Lard, Sunflower Oil, Cellulose, Wheat Starch, Dextrinised Starch, Minerals, and 
Vitamins.  
Lab chow diet: Cereal Grains, Meat Offal Meal, Fish Offal Meal, Whey Powder, Vegetable Oils, Soybean Protein, Cereal 
Offal, Corn Offal, Minerals, and Vitamins. 
 
2.2. Glucose tolerance test 
Mice were fasted overnight (16 hrs) before a glucose tolerance test (GTT) was performed to assess 
glucose clearance, following an intraperitoneal (i.p) injection of glucose (0.5 g/kg; Sigma-Aldrich, St 
Louis, MO). Blood samples were taken from the tail vein before and 30, 60 and 120 minutes following 
the injection of glucose. Blood glucose was measured using an Accu-Chek glucometer (Roche 
Diagnostics GmbH Mannheim, Germany). 
2.3. Insulin sensitivity test  
Mice were fasted for 5 hours before an insulin sensitivity test (IST) was performed to assess glucose 
clearance, following an i.p. injection of insulin (0.75 U/kg; Sigma-Aldrich, St Louis, MO). Blood samples 
were taken from the tail vein before and at 30, 60 and 120 minutes following the injection of insulin. 
Blood glucose was measured using an Accu-Chek glucometer (Roche Diagnostics GmbH Mannheim, 
Germany). 
2.4. Tissue collection and sample preparations 
For tissue analysis, mice were euthanised at week 21 of the experiment. Tissue was dissected from the 
mice and immediately frozen in liquid nitrogen before being stored at -80 °C.  
2.5. Oil Red O staining 
Oil Red O staining was used to examine hepatic lipid accumulation as described previously (Kudo, 
Tamagawa, Kawashima et al., 2007). Briefly, frozen liver sections (10 μm) were stained with 0.5% Oil 
Red O (Sigma-Aldrich) for 15 minutes and then washed. Three fields from three sections of each 
mouse were viewed under a Leica microscope, and digital photographs were captured. Image J 
software (http://imagej.nih.gov/ij/download.html) was used to quantify the staining, which corresponds 
to the percentage of stained lipid droplets on an area of each slide (Mehlem, Hagberg, Muhl et al., 
2013).  
2.6. Haematoxylin and Eosin (H&E) staining 
To determine the degree of liver damage fresh frozen liver sections (10 μm) were stained with 
Haematoxylin and Eosin for 30 seconds each. Three fields from three sections of each mouse were 
viewed under a Leica microscope and digital photographs were captured. The histological parameters 
of steatosis and ballooning were scored according to the method described by Kleiner and colleagues 
(Kleiner, Brunt, Van Natta et al., 2005). The steatosis grades were as follows: 0, <5%; 1, 5%–33%; 2, 
>33%–66%; 3, >66%. The ballooning classifications were grouped as: 0, no ballooning cells; 1, few 
ballooning cells; 2, many cells/prominent ballooning. 
2.7. Immunohistochemistry 
Liver sections fixed in 10% Formalin were embedded in paraffin before being sectioned (5 μm) onto 
Polylysine™ slides. Slides were incubated overnight at 4 °C with anti-rabbit F4/80 (1:150 Santa Cruz 
Biotechnology, Dallas, TX) diluted in blocking buffer as described previously (Dinh, Szabo, Camer et 
al., 2015). Three fields from three sections of each mouse were viewed under a Leica microscope and 
digital photographs were captured. Image J software was used to quantify the area of F4/80 
immunoreactivity on each slide.  
2.8. Extraction of nuclear and cytosolic proteins 
Nuclear and cytosolic proteins were extracted from liver tissue as described by Mobasher et al 
(Mobasher, Gonzalez-Rodriguez, Santamaria et al., 2013). Briefly, liver tissue was homogenised in a 
solution containing 10Mm HEPES-KOH (pH 7.9), 10mM KCL, 1.5mM MgCl2, 0.5mM DTT, 0.2mM 
PMSF, and protease and phosphatase inhibitors (buffer A) before incubation on ice, vortexing and 
centrifugation. Following centrifugation, the supernatant containing the cytosolic fraction was collected 
and frozen at -80 °C until use. The remaining pellet was resuspended in a solution containing 20mM 
HEPES-KOH (pH 7.9), 400mM NaCl, 1.5 mM MgCl2 0.2mM EDTA, 15% glycerol, 0.5mM DTT, 0.2mM 
PMSF and protease and phosphatase inhibitors (buffer B) before further centrifugation. Following 
multiple washes with buffer b and centrifugation of the pellet, the supernatant containing the nuclear 
fraction was collected and stored at -80 °C until use.  
2.9. Western Blot analysis 
For total protein extraction, the frozen liver tissue was homogenised in Nonidet P-40 lysis buffer. The 
following antibodies were used for western blotting: Nrf2 (sc-722), IL-1β (sc-7884), IL-6 (sc-7920) and 
BDNF (sc-546) (Santa Cruz Biotechnology, Dallas, TX); pIKK (#2697), STAT3 (#4904), FOXO1 
(#2880), SOCS3 (#2932), and PTP1B (#5311) (Cell Signalling Technology, Beverly, MA). Both nuclear 
and cytosolic protein levels of Nrf2 were analysed. The bands corresponding to the proteins of interest 
were scanned and the band density analysed using the automatic imaging analysis system, Quantity 
One (Bio-Rad Laboratories, Hercules, California) as described in our previous study (Camer, Yu, Szabo 
et al., 2015). All quantitative analyses for total and cytosolic proteins were normalised to β-actin. 
Nuclear proteins were normalised to Lamin B. 
2.10. Luminex Assay 
Blood was collected in EDTA tubes from mice following euthanasia. Following centrifugation, plasma 
was extracted, collected and stored at -80 °C. Plasma insulin levels were measured using Luminex 
assay kits according to the manufacturer’s instructions (Bio-Rad Diabetes Kit, Sydney). 
2.11. RNA isolation and RT-PCR 
Total RNA was extracted from mouse liver using the Aurum total RNA mini kit (Bio-Rad Laboratories, 
Hercules, CA) before being reversed transcribed to complimentary first strand DNA with a high-capacity 
cDNA reverse transcription kit (AB Applied Biosystems, California, USA) according to the 
manufacturer’s directions. Quantitative real-time PCR (RT-PCR) was performed using a Lightcycler 480 
real time PCR system (F.Hoffmann-La Roche Ltd, Switzerland). A 20ul final reaction volume containing 
cDNA sample and SYBR green I master mix was used to perform the experiment. Briefly, amplification 
was carried out with 45 cycles of 95 °C for 10 seconds, 60 °C for 30 seconds and 72 °C for 30 
seconds. The expression of mRNA was normalised to an internal control, GADPH. The degree of 
mRNA expression was calculated using the comparative threshold cycle value (Ct) method, using the 
formula 2–ΔΔCt (where ΔΔCt =ΔCt sample - ΔCt reference) as described previously (Livak and 
Schmittgen, 2001). 
2.12. Statistics 
Data were analysed using the statistical package SPSS 20 (SPSS, Chicago, IL). Data was first tested 
for normality using a Kolmogorov-Smirnov normality test. Differences between mice fed a LC, HF, and 
HF plus BM diet were then determined by one-way analysis of variance (ANOVA). This was followed by 
the post hoc Tukey-Kramer honestly significant difference (HSD) test for multiple comparisons among 
the groups. A p value of <0.05 was considered statistically significant. Values are expressed as the 
mean ± SEM. 
3. Results  
3.1. Bardoxolone methyl treatment prevented HF diet-induced insulin resistance 
To explore the role of BM in glucose homeostasis and insulin sensitivity, glucose tolerance tests (GTTs) 
and insulin sensitivity tests (ISTs) were performed (Figures 1A and C). HF diet fed mice had 
significantly higher blood glucose levels during fasting (0 minute) and 120 minutes following an i.p. 
injection of glucose compared to LC fed mice. However, administration of BM normalised blood glucose 
levels at 120 minutes in the GTT test in HF diet fed mice (-18.07%, p = 0.015), with significance 
confirmed with area under the curve (AUC) analysis (Figure 1B). However, BM did not prevent HF diet-
induced increases in fasting blood glucose levels (p>0.05). Consistent with the effect of BM on 
improving glucose clearance, BM treatment also reduced blood glucose levels during the IST in mice 
fed a HF diet (Figure 1C). HF diet fed mice had significantly higher blood glucose levels at fasting and 
30, 60 and 120 minutes following insulin injection compared to LC fed mice. BM treatment significantly 
decreased blood glucose levels at 30 and 60 minutes post i.p. insulin injection (Figure 1C) in the mice 
fed a HF diet, with significance confirmed with area under the curve (AUC) analysis (Figure 1D) (Blood 
glucose levels 30 minutes following i.p. insulin injection: -34.23%, p = <0.001; Blood glucose levels 60 
minutes following i.p. insulin injection: -25.92%, p = 0.048).  
Fasting plasma insulin levels were examined to determine if BM could prevent HF diet-induced 
hyperinsulemia. As expected, mice fed a HF diet for 21 weeks had significantly elevated plasma insulin 
levels compared to LC fed mice, which was attenuated by BM administration (Figure 1E). To determine 
if BM treatment could prevent HF diet-induced insulin resistance, HOMA-IR was calculated. HF diet-fed 
mice were found to have a significantly elevated HOMA-IR compared to LC group (Figure 1F). 
However, BM administration in HF diet fed mice significantly prevented this increase in HOMA-IR. 
These results suggest that BM can prevent hyperinsulemia and insulin resistance induced by a chronic 
HF diet. 
 
Figure 1. Effect of chronic administration of bardoxolone methyl (BM) on glucose tolerance (A, B), insulin sensitivity (C, D), 
hyperinsulemia (E) and HOMA-IR (F) in mice fed a high-fat (HF) diet for 21 weeks (n=7 per group). *, p = <.0.05 vs. lab 
chow (LC) group, #, p= <0.05 vs. HF group values are means ±SEM. 
 
We evaluated the effect of BM on the expression of molecules involved in insulin resistance and 
glucose metabolism in the liver using western blotting and RT-PCR analysis. Western blot showed that 
a HF diet elevated hepatic PTP1B and FOXO1, and reduced BDNF protein expression, which was 
significantly reversed by BM treatment (Figure 2A). No significant differences in protein expression of 
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BM on hepatic lipid content, ballooning and steatosis (Figure 3C). Histological examination revealed 
that the hepatocytes of HF diet fed mice were enlarged and contained large cytoplasmic lipid droplets 
compared to LC fed mice (Lipid content area (%) difference: -61.94%, p = <0.001; ballooning 
difference: -72.78%, p = <0.001; steatosis difference: -58.65%, p = <0.001). This change in hepatic 
cellular morphology was prevented by BM treatment, where the percentage of hepatic lipid area, 
ballooning, and steatosis were significantly lower compared to the HF diet fed group (Lipid content area 
(%) difference: -61.94%, p = <0.001; ballooning difference: -72.78%, p = <0.001; steatosis difference: 
62.02%, p = <0.001) (Table 2). 
Fatty acid metabolism-related genes in the liver were measured using RT-PCR in order to assess if 
these markers were responsible for BM’s ability to prevent HF diet induced hepatic fat accumulation 
(Figure 3D). The results showed that BM prevented HF diet-induced decreases in the β oxidation gene, 
ACOX (HF vs. LC difference: -98.84%, p = <0.001; HF vs. BM difference: -94.02%, p = <0.001). 
However the expression of ACOX was still significantly higher in the LC group compared to HF diet fed 
mice treated with BM (LC vs. BM difference: -80.61%, p = <0.001). Furthermore, the levels of the 
lipogenic genes SCD1 and FAS were significantly lower in the BM group compared to the untreated HF 
diet group. However, FAS expression in the LC group was significantly higher than both the HF diet 
group and BM group, and there were no significant differences between the LC and HF diet group in 
SCD1 mRNA expression. In addition, there were no significant differences between ACC mRNA 
expression in the HF and BM groups. However, ACC mRNA expression was significantly lower in BM 
treated mice compared to LC fed mice. These results suggest that BM prevents HF diet-induced fat 
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diet-induced increase in IL-6 and STAT3 was prevented by BM treatment (Figure 4C). There were no 
significant differences in the expression of hepatic pIKK or IL-1β between the groups. In addition, 
nuclear protein levels of Nrf2 were significantly reduced in the livers of HF diet fed mice. However, this 
reduction was significantly prevented by BM treatment (Figure 4D). There were no significant 
differences in hepatic cytosolic Nrf2 protein levels among any of the groups. Furthermore, RT-PCR 
analysis showed a significant increase in TNFα and IL-6 mRNA expression, and decrease in Nrf2 
mRNA expression in mice fed a HF diet (Figure 4E). The alterations in TNFα and Nrf2 mRNA levels 
were significantly prevented by BM administration. However, BM treatment was unable to prevent HF 
diet-induced elevations in IL-6 mRNA expression. No significant differences were found in the mRNA 
expression of IKKβ and IKKε between any of the groups. These results suggest that BM prevents the 
development of HF diet induced hepatic macrophage infiltration by regulating proinflammatory 
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current study, we found that BM not only prevents HF diet-induced hepatic insulin resistance and 
inflammation, but it also reduces liver injury by preventing the development of fat accumulation and 
progression to hepatic steatosis. 
A number of studies suggest that obesity-induced inflammation plays an important role in the 
development of insulin resistance (Emanuela et al., 2012,Boden and Shulman, 2002). A HF diet can 
promote insulin resistance by elevating proteins levels of the negative regulator, PTP1B, which impairs 
hepatic insulin signalling (Zabolotny et al., 2008). In the liver, insulin signal transduction suppresses 
hepatic glucose production through the inhibition of gluconeogenesis (Saltiel and Kahn, 2001). The 
hepatic insulin signalling cascade results in the inhibition of FOXO1, a transcription factor that promotes 
the expression of gluconeogenic genes such as G6Pase (Schmoll, Walker, Alessi et al., 2000,Yeagley, 
Guo, Unterman et al., 2001). Mice lacking the hepatic FOXO1 gene display reductions in 
gluconeogenic gene expression, resulting in reduced glucose production and improved glucose 
clearance (Matsumoto, Pocai, Rossetti et al., 2007). BDNF is also an important molecule for preventing 
insulin resistance that increases glucose metabolism, resulting in reduced blood glucose levels (Kuroda 
et al., 2003,Hariharan et al., 1997). Our study demonstrated that BM treatment in mice fed a HF diet for 
21 weeks reduced hepatic PTP1B and FOXO1, and increased BDNF protein levels, which was coupled 
with a reduction in plasma insulin levels. In addition, the HF diet-induced decreases in IR and IRS-1, 
and increase in G6Pase mRNA expression was significantly prevented by BM treatment. Overall, our 
results suggest that the action of BM in preventing HF diet-induced glucose intolerance and insulin 
resistance was through, at least partially, inhibiting FOXO1/G6Pase mediated hepatic glucose 
production. 
Obesity from a HF diet is known to result in the accumulation of fat into the liver (Marchesini et al., 
2001). A HF diet results in an increase in the expression of the hepatic lipogenic genes, ACC, FAS and 
SCD1 and fat accumulation in the livers of mice fed a HF diet (Choi, Um, Ahn et al., 2014). Moreover, 
hamsters fed a HF diet have an increase in hepatic lipidemia that is coupled with a decrease in mRNA 
expression of the β fatty oxidation gene, ACOX (Choi, Gwon, Ahn et al., 2013). We found that chronic 
HF diet feeding resulted in an accumulation of fat and hepatocyte injury in the liver and was associated 
with an increase in SCD1 and FAS, and a decrease in ACOX genes. These alterations were prevented 
by BM administration. These results suggest that HF diet-induce fat accumulation in the liver and 
associated decreases in a β oxidation gene can be prevented by BM administration. 
Obesity-induced fat accumulation is associated with the infiltration of macrophages into adipose tissue, 
where they promote the release of proinflammatory cytokines such as TNFα and IL-6 (Wellen and 
Hotamisligil, 2005). IL-6 has been found to increase STAT3 levels to promote inflammatory signalling in 
human mammary epithelial (hTERT-HME1) cells (Yang et al., 2007). We found that there was 
increased macrophage infiltration, coupled with an increase of the proteins IL-6, and STAT3, and the 
IL-6 and TNFα genes in the livers of mice chronically fed a HF diet. Furthermore, our results 
demonstrated that HF diet-induced macrophage infiltration, along with IL-6 and STAT3 protein levels 
and TNFα mRNA expression could be prevented by BM administration. However, although BM 
prevented HF diet induced increases in IL-6 protein expression, it failed to prevent HF diet induced 
increases in IL-6 mRNA expression, attributed to the post transcription of IL-6. One of the possible 
mechanisms for the anti-inflammatory effects of BM in the liver includes preventing the activation of IL-
6, resulting in reduced STAT3 and preventing TNFα mRNA expression which all contribute to 
attenuating the proinflammatory response.  
BM has been reported to be one of the most potent known activators of Nrf2 in several peripheral 
tissues including the eyes and kidneys (Camer, Yu, Szabo et al., 2014). In the livers of mice, Nrf2 
activation causes reduced expression of the inflammatory cytokines, TNFα and IL-6 (Liu, Wu, Lu et al., 
2013,Wang, Cui, Li et al., 2013). Nrf2 deletion is associated with increased liver weight gain, and 
hepatic steatosis in mice fed a HF diet (Wang et al., 2013). Furthermore, mice deficient in Nrf2 and fed 
a HF diet have been reported to show rapid development of hepatic steatosis and associated increases 
in the fatty acid lipogenic genes ACC, FAS and SCD1 (Okada, Warabi, Sugimoto et al., 2013) and 
reduction in the β oxidation gene, ACOX (Tanaka, Ikeda, Yamamoto et al., 2012). In addition, HF diet-
induced hepatic steatosis in mice can be improved through regulation of Nrf2 (Yang, Li, Liu et al., 
2014). In our study, BM administration prevented HF diet induced decreases in Nrf2 protein levels in 
the nucleus and Nrf2 gene expression. This suggests the ability of BM to prevent HF diet induced 
elevations in proinflammatory signalling molecules and fat accumulation in the liver may be due to its 
ability to regulate the expression of the Nrf2 gene and Nrf2 nuclear protein levels. 
In conclusion, our findings suggest that chronic supplementation with BM may play an important role in 
preventing the actions of a HF diet in the development of inflammation, insulin resistance and hepatic 
steatosis in mice. A proposed model of the potential molecular mechanisms targeted by BM in mice fed 
a HF diet is presented in Figure 5. Since obesity-induced inflammation and insulin resistance has been 
implicated in the progression of liver disease, BM may have beneficial effects in preventing the 
progression of HF diet induced liver steatosis. With further research and eventual human clinical trials, 
the possibility of using BM for the prevention of insulin resistance and associated development of 
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